INKT shares traded at $11.48 after MiNK Therapeutics released new clinical updates, reflecting a $0.22 decline, or 1.88%, during Thursday's session. The company announced initial results from its Phase 2 study evaluating agenT-797 in severe hypoxemic pneumonia.

Trial Data Shows Early Clinical Progress

MiNK Therapeutics presented the findings at the 2026 Military Health System Research Symposium, with Dr. Terese Hammond leading the presentation. Researchers from the First Lviv Territorial Medical Union in Ukraine co-authored the data alongside MiNK Therapeutics. The choice of venue underscores the program's alignment with defense medical priorities, as the Department of Defense has increasingly prioritized treatments for multidrug-resistant infections and respiratory failure affecting deployed service members.

Severe lung injury carries high mortality, and no approved therapy currently reduces it effectively. Standard treatment for acute respiratory distress syndrome and severe pneumonia remains largely supportive—mechanical ventilation, fluid management, and broad-spectrum antibiotics—leaving a significant unmet need across both civilian and military medicine. Multidrug-resistant infections frequently worsen outcomes in conflict zones, where traditional antibiotics often fail. agenT-797 is designed to restore barrier immunity and limit inflammatory lung damage in these challenging settings.

Patients treated with agenT-797 remained alive through Day 28, with noticeable improvements in hemodynamics. Oxygenation levels rose alongside mental status improvements within the treated group. Microbiological testing confirmed control of baseline infections in these critically ill patients. Blood and lung fluid analyses also showed reduced inflammatory markers following treatment.

Physician and Executive Commentary

Dr. Hammond noted that patients entered the study facing severe respiratory failure and substantial medical risk. She reported encouraging improvements in oxygenation, infection control, and markers associated with inflammation reduction. The biological changes aligned with earlier findings MiNK Therapeutics presented at the ASGCT and ATS conferences.

Jennifer Buell, President and CEO of MiNK Therapeutics, emphasized the trial's rapid execution timeline. She stated that the team activated the randomized trial and dosed the first patient within days of approval. Buell added that Day 28 observations followed weeks later, despite the active conflict environment surrounding the site.

Buell highlighted the value of an off-the-shelf therapy that eliminates patient-specific manufacturing steps. She noted that the treatment avoids HLA matching and lymphodepletion, unlike many competing cell therapies. While most approved cell therapies target cancer—CAR-T treatments, for example, require weeks of patient-specific manufacturing—allogeneic platforms like agenT-797 are being explored for infectious and inflammatory diseases where treatment windows can be measured in hours rather than weeks. MiNK Therapeutics stated it remains focused on supporting medical readiness for service members and critically ill patients.

Company Background and Pipeline Direction

MiNK Therapeutics develops allogeneic invariant natural killer T-cell therapies for cancer and immune-related disorders. iNKT cells are a rare T-cell subset that recognizes lipid antigens and bridges innate and adaptive immunity, a mechanism distinct from the antigen-specific targeting used in conventional T-cell therapies. The company positions agenT-797 as a scalable option for austere and resource-limited medical environments. No major serious adverse events tied to agenT-797 were reported among the initial treated patients.

MiNK Therapeutics continues to advance the program following the Phase 2 update. The company plans further data disclosures as enrollment and treatment progress across sites. MiNK Therapeutics remains focused on expanding its iNKT-cell platform across additional disease indications.